logo
Plus   Neg
Share
Email

Merck: EU Approves KEYTRUDA Plus Chemotherapy To Treat Metastatic Squamous NSCLC

Merck (MRK) announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adults with metastatic squamous non-small cell lung cancer. The approval allows marketing of the KEYTRUDA combination in all 28 EU member states plus Iceland, Lichtenstein and Norway, at the approved dose of 200 mg every three weeks until disease progression or unacceptable toxicity.

Roy Baynes, head of global clinical development, chief medical officer, Merck Research Laboratories, said: "This is a meaningful treatment advance as an anti-PD-1 combination therapy is now approved in Europe for this type of non-small cell lung cancer. With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit from combination therapy with KEYTRUDA."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
NetApp Inc. (NTAP) Wednesday reported a fourth-quarter profit that fell short of Wall Street estimates, as revenues slipped 3 percent. Shares of the company slipped 6% in extended trading session after its first-quarter outlook was also short of current expectations. Sunnyvale, California-based NetApp... The release of $20 bill featuring Harriet Tubman, an American abolitionist and political activist, has been postponed. The redesign of the $20 bill featuring Tubman will no longer be unveiled in 2020, Treasury Secretary Steven Mnuchin said. The government was planning to unveil the redesigned $20... An analyst at Goldman Sachs Inc. has warned that Apple Inc.'s earnings could drop by 29 percent if China were to retaliate in the trade war against the U.S. with a ban on sales of Apple products in that country. The iPhone maker's China business accounted for 17.6 percent of its total sales in the recent second quarter.
Follow RTT